Jude Onyia Sells 2,331 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Jude Onyia sold 2,331 shares of the stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the sale, the insider now owns 15,449 shares of the company’s stock, valued at $1,951,054.21. This represents a 13.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Neurocrine Biosciences Trading Down 1.0 %

NASDAQ NBIX opened at $126.42 on Friday. Neurocrine Biosciences, Inc. has a 12 month low of $110.95 and a 12 month high of $157.98. The company’s 50-day moving average price is $120.07 and its 200-day moving average price is $131.19. The stock has a market cap of $12.80 billion, a PE ratio of 33.89 and a beta of 0.34.

Hedge Funds Weigh In On Neurocrine Biosciences

Institutional investors have recently modified their holdings of the stock. State Street Corp boosted its holdings in shares of Neurocrine Biosciences by 11.7% in the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock valued at $593,186,000 after purchasing an additional 539,936 shares during the period. Renaissance Technologies LLC grew its position in shares of Neurocrine Biosciences by 9.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock worth $339,790,000 after buying an additional 216,500 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Neurocrine Biosciences by 2.2% during the third quarter. Geode Capital Management LLC now owns 1,859,232 shares of the company’s stock valued at $213,773,000 after buying an additional 39,610 shares during the period. AQR Capital Management LLC raised its holdings in shares of Neurocrine Biosciences by 23.0% in the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock valued at $166,959,000 after acquiring an additional 228,444 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Neurocrine Biosciences by 1.4% in the second quarter. Bank of New York Mellon Corp now owns 934,404 shares of the company’s stock worth $128,639,000 after acquiring an additional 13,069 shares during the period. 92.59% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $131.00 to $159.00 in a report on Thursday, August 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research note on Monday, November 11th. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a report on Monday, September 16th. Finally, HC Wainwright restated a “buy” rating and set a $190.00 price target on shares of Neurocrine Biosciences in a report on Friday, November 1st. Five research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.